The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin

Nicole M Gerlanc,1 Jennifer Cai,2 Joseph Tkacz,1 Susan C Bolge,2 Brenna L Brady1 1Health Analytics, LLC Columbia, MD, USA; 2Janssen Scientific Affairs, LLC Titusville, NJ, USA Objective: Type 2 diabetes mellitus (T2DM) is a chronic condition complicated by being overweight or obese. This study used...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gerlanc NM, Cai J, Tkacz J, Bolge SC, Brady BL
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Diabetes Survey Patient Experience Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/43fc34719f7245eb8bfe5006f4af0d0b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:43fc34719f7245eb8bfe5006f4af0d0b
record_format	dspace
spelling	oai:doaj.org-article:43fc34719f7245eb8bfe5006f4af0d0b2021-12-02T07:54:28ZThe association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin1178-7007https://doaj.org/article/43fc34719f7245eb8bfe5006f4af0d0b2017-03-01T00:00:00Zhttps://www.dovepress.com/the-association-of-weight-loss-with-patient-experience-and-outcomes-in-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Nicole M Gerlanc,1 Jennifer Cai,2 Joseph Tkacz,1 Susan C Bolge,2 Brenna L Brady1 1Health Analytics, LLC Columbia, MD, USA; 2Janssen Scientific Affairs, LLC Titusville, NJ, USA Objective: Type 2 diabetes mellitus (T2DM) is a chronic condition complicated by being overweight or obese. This study used a patient survey to assess health, satisfaction, and diabetes self-management in relation to weight management.Methods: A survey including the Current Health Satisfaction Questionnaire, Diabetes Distress Scale, and Diabetes Treatment Satisfaction Questionnaire was administered using an online platform to a sample of 205 patients with T2DM prescribed canagliflozin. Patients were placed into 5 groups based on their self-reported weight change since initiation of canagliflozin: Lost >10 lbs, Lost 5–10 lbs, Lost <5 lbs, No Change, and Gained Weight. One-way ANOVAs, Kruskall–Wallis tests, and multivariable regression were used to explore differences between weight loss groups. Results: The majority of patients (66.8%) reported losing weight. Compared to other groups, patients who lost >10 lbs were more likely to be engaged in a weight loss program for at least 6 months. Patients in the Lost >10 lbs and Lost 5–10 lbs groups reported the greatest satisfaction with canagliflozin (p<0.05 for both). Multivariable analyses controlling for patient demographic and treatment characteristics revealed that losing >10 lbs was associated with reduced diabetes distress, improved A1c and blood glucose levels, and decreased perceived frequency of hyperglycemia (p<0.05).Conclusion: Increased positive patient outcomes, engagement in diabetes self-management, and medication satisfaction were observed among patients who reported weight loss. These findings suggest that a T2DM regimen that includes canagliflozin as part of a weight loss regimen can help improve patient outcomes and experiences with T2DM. Keywords: T2DM, patient outcomes, diabetes self-management, SGLT2 inhibitor, weight managementGerlanc NMCai JTkacz JBolge SCBrady BLDove Medical PressarticleDiabetesSurveyPatient ExperienceSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 10, Pp 89-99 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diabetes Survey Patient Experience Specialties of internal medicine RC581-951
spellingShingle	Diabetes Survey Patient Experience Specialties of internal medicine RC581-951 Gerlanc NM Cai J Tkacz J Bolge SC Brady BL The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin
description	Nicole M Gerlanc,1 Jennifer Cai,2 Joseph Tkacz,1 Susan C Bolge,2 Brenna L Brady1 1Health Analytics, LLC Columbia, MD, USA; 2Janssen Scientific Affairs, LLC Titusville, NJ, USA Objective: Type 2 diabetes mellitus (T2DM) is a chronic condition complicated by being overweight or obese. This study used a patient survey to assess health, satisfaction, and diabetes self-management in relation to weight management.Methods: A survey including the Current Health Satisfaction Questionnaire, Diabetes Distress Scale, and Diabetes Treatment Satisfaction Questionnaire was administered using an online platform to a sample of 205 patients with T2DM prescribed canagliflozin. Patients were placed into 5 groups based on their self-reported weight change since initiation of canagliflozin: Lost >10 lbs, Lost 5–10 lbs, Lost <5 lbs, No Change, and Gained Weight. One-way ANOVAs, Kruskall–Wallis tests, and multivariable regression were used to explore differences between weight loss groups. Results: The majority of patients (66.8%) reported losing weight. Compared to other groups, patients who lost >10 lbs were more likely to be engaged in a weight loss program for at least 6 months. Patients in the Lost >10 lbs and Lost 5–10 lbs groups reported the greatest satisfaction with canagliflozin (p<0.05 for both). Multivariable analyses controlling for patient demographic and treatment characteristics revealed that losing >10 lbs was associated with reduced diabetes distress, improved A1c and blood glucose levels, and decreased perceived frequency of hyperglycemia (p<0.05).Conclusion: Increased positive patient outcomes, engagement in diabetes self-management, and medication satisfaction were observed among patients who reported weight loss. These findings suggest that a T2DM regimen that includes canagliflozin as part of a weight loss regimen can help improve patient outcomes and experiences with T2DM. Keywords: T2DM, patient outcomes, diabetes self-management, SGLT2 inhibitor, weight management
format	article
author	Gerlanc NM Cai J Tkacz J Bolge SC Brady BL
author_facet	Gerlanc NM Cai J Tkacz J Bolge SC Brady BL
author_sort	Gerlanc NM
title	The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin
title_short	The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin
title_full	The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin
title_fullStr	The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin
title_full_unstemmed	The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin
title_sort	association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/43fc34719f7245eb8bfe5006f4af0d0b
work_keys_str_mv	AT gerlancnm theassociationofweightlosswithpatientexperienceandoutcomesinapopulationofpatientswithtype2diabetesmellitusprescribedcanagliflozin AT caij theassociationofweightlosswithpatientexperienceandoutcomesinapopulationofpatientswithtype2diabetesmellitusprescribedcanagliflozin AT tkaczj theassociationofweightlosswithpatientexperienceandoutcomesinapopulationofpatientswithtype2diabetesmellitusprescribedcanagliflozin AT bolgesc theassociationofweightlosswithpatientexperienceandoutcomesinapopulationofpatientswithtype2diabetesmellitusprescribedcanagliflozin AT bradybl theassociationofweightlosswithpatientexperienceandoutcomesinapopulationofpatientswithtype2diabetesmellitusprescribedcanagliflozin AT gerlancnm associationofweightlosswithpatientexperienceandoutcomesinapopulationofpatientswithtype2diabetesmellitusprescribedcanagliflozin AT caij associationofweightlosswithpatientexperienceandoutcomesinapopulationofpatientswithtype2diabetesmellitusprescribedcanagliflozin AT tkaczj associationofweightlosswithpatientexperienceandoutcomesinapopulationofpatientswithtype2diabetesmellitusprescribedcanagliflozin AT bolgesc associationofweightlosswithpatientexperienceandoutcomesinapopulationofpatientswithtype2diabetesmellitusprescribedcanagliflozin AT bradybl associationofweightlosswithpatientexperienceandoutcomesinapopulationofpatientswithtype2diabetesmellitusprescribedcanagliflozin
_version_	1718399098639351808

The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin

Ejemplares similares